NCT06135896View on ClinicalTrials.gov

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Unresectable Pancreatic CancerUnresectable Bile Duct CarcinomaUnresectable Biliary Tract Carcinoma
Interventions
DRUG

Tripegfilgrastim

Tripegfilgrastim to reduce the risk of severe neutropenia in patients with unresectable pancreaticobiliary cancers

Trial Locations (1)

10408

RECRUITING

NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,, Goyang-si

All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

lead

National Cancer Center, Korea

OTHER_GOV